CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter

Samrat Roy Choudhury, Yi Cui, Katarzyna Lubecka, Barbara Stefanska, Joseph Irudayaraj

Research output: Contribution to journalArticle

Abstract

DNA hypermethylation at the promoter of tumour-suppressor genes is tightly correlated with their transcriptional repression and recognized as the hallmark of majority of cancers. Epigenetic silencing of tumour suppressor genes impairs their cellular functions and activates a cascade of events driving cell transformation and cancer progression. Here, we examine site-specific and spatiotemporal alteration in DNA methylation at a target region in BRCA1 gene promoter, a model tumour suppressor gene. We have developed a programmable CRISPR-Cas9 based demethylase tool containing the deactivated Cas9 (dCas9) fused to the catalytic domain (CD) of Ten-Eleven Translocation (TET) dioxygenase1 (TET1CD). The fusion protein selectively demethylates targeted regions within BRCA1 promoter as directed by the designed single-guide RNAs (sgRNA), leading to the transcriptional up-regulation of the gene. We also noticed the increment in 5-hydroxymethylation content (5-hmC) at the target DNA site undergoing the most profound demethylation. It confirms the catalytic activity of TET1 in TET1-dCas9 fusion proteins-mediated demethylation at these target sequences. The modular design of the fusion constructs presented here allows for the selective substitution of other chromatin or DNA modifying enzymes and for locispecific targeting to uncover epigenetic regulatory pathways at gene promoters and other selected genomic regions.

Original languageEnglish (US)
Pages (from-to)46545-46556
Number of pages12
JournalOncotarget
Volume7
Issue number29
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Clustered Regularly Interspaced Short Palindromic Repeats
Tumor Suppressor Genes
Epigenomics
DNA
Guide RNA
BRCA1 Gene
DNA Methylation
Genes
Chromatin
Catalytic Domain
Neoplasms
Proteins
Up-Regulation
Enzymes

Keywords

  • BRCA1
  • CRISPR-dCas9
  • DNA demethylation
  • Gene activation
  • TET1

ASJC Scopus subject areas

  • Oncology

Cite this

CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter. / Choudhury, Samrat Roy; Cui, Yi; Lubecka, Katarzyna; Stefanska, Barbara; Irudayaraj, Joseph.

In: Oncotarget, Vol. 7, No. 29, 01.01.2016, p. 46545-46556.

Research output: Contribution to journalArticle

Choudhury, Samrat Roy ; Cui, Yi ; Lubecka, Katarzyna ; Stefanska, Barbara ; Irudayaraj, Joseph. / CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter. In: Oncotarget. 2016 ; Vol. 7, No. 29. pp. 46545-46556.
@article{da0eafa0b5894c2bbe65fc197475f84c,
title = "CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter",
abstract = "DNA hypermethylation at the promoter of tumour-suppressor genes is tightly correlated with their transcriptional repression and recognized as the hallmark of majority of cancers. Epigenetic silencing of tumour suppressor genes impairs their cellular functions and activates a cascade of events driving cell transformation and cancer progression. Here, we examine site-specific and spatiotemporal alteration in DNA methylation at a target region in BRCA1 gene promoter, a model tumour suppressor gene. We have developed a programmable CRISPR-Cas9 based demethylase tool containing the deactivated Cas9 (dCas9) fused to the catalytic domain (CD) of Ten-Eleven Translocation (TET) dioxygenase1 (TET1CD). The fusion protein selectively demethylates targeted regions within BRCA1 promoter as directed by the designed single-guide RNAs (sgRNA), leading to the transcriptional up-regulation of the gene. We also noticed the increment in 5-hydroxymethylation content (5-hmC) at the target DNA site undergoing the most profound demethylation. It confirms the catalytic activity of TET1 in TET1-dCas9 fusion proteins-mediated demethylation at these target sequences. The modular design of the fusion constructs presented here allows for the selective substitution of other chromatin or DNA modifying enzymes and for locispecific targeting to uncover epigenetic regulatory pathways at gene promoters and other selected genomic regions.",
keywords = "BRCA1, CRISPR-dCas9, DNA demethylation, Gene activation, TET1",
author = "Choudhury, {Samrat Roy} and Yi Cui and Katarzyna Lubecka and Barbara Stefanska and Joseph Irudayaraj",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.10234",
language = "English (US)",
volume = "7",
pages = "46545--46556",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "29",

}

TY - JOUR

T1 - CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter

AU - Choudhury, Samrat Roy

AU - Cui, Yi

AU - Lubecka, Katarzyna

AU - Stefanska, Barbara

AU - Irudayaraj, Joseph

PY - 2016/1/1

Y1 - 2016/1/1

N2 - DNA hypermethylation at the promoter of tumour-suppressor genes is tightly correlated with their transcriptional repression and recognized as the hallmark of majority of cancers. Epigenetic silencing of tumour suppressor genes impairs their cellular functions and activates a cascade of events driving cell transformation and cancer progression. Here, we examine site-specific and spatiotemporal alteration in DNA methylation at a target region in BRCA1 gene promoter, a model tumour suppressor gene. We have developed a programmable CRISPR-Cas9 based demethylase tool containing the deactivated Cas9 (dCas9) fused to the catalytic domain (CD) of Ten-Eleven Translocation (TET) dioxygenase1 (TET1CD). The fusion protein selectively demethylates targeted regions within BRCA1 promoter as directed by the designed single-guide RNAs (sgRNA), leading to the transcriptional up-regulation of the gene. We also noticed the increment in 5-hydroxymethylation content (5-hmC) at the target DNA site undergoing the most profound demethylation. It confirms the catalytic activity of TET1 in TET1-dCas9 fusion proteins-mediated demethylation at these target sequences. The modular design of the fusion constructs presented here allows for the selective substitution of other chromatin or DNA modifying enzymes and for locispecific targeting to uncover epigenetic regulatory pathways at gene promoters and other selected genomic regions.

AB - DNA hypermethylation at the promoter of tumour-suppressor genes is tightly correlated with their transcriptional repression and recognized as the hallmark of majority of cancers. Epigenetic silencing of tumour suppressor genes impairs their cellular functions and activates a cascade of events driving cell transformation and cancer progression. Here, we examine site-specific and spatiotemporal alteration in DNA methylation at a target region in BRCA1 gene promoter, a model tumour suppressor gene. We have developed a programmable CRISPR-Cas9 based demethylase tool containing the deactivated Cas9 (dCas9) fused to the catalytic domain (CD) of Ten-Eleven Translocation (TET) dioxygenase1 (TET1CD). The fusion protein selectively demethylates targeted regions within BRCA1 promoter as directed by the designed single-guide RNAs (sgRNA), leading to the transcriptional up-regulation of the gene. We also noticed the increment in 5-hydroxymethylation content (5-hmC) at the target DNA site undergoing the most profound demethylation. It confirms the catalytic activity of TET1 in TET1-dCas9 fusion proteins-mediated demethylation at these target sequences. The modular design of the fusion constructs presented here allows for the selective substitution of other chromatin or DNA modifying enzymes and for locispecific targeting to uncover epigenetic regulatory pathways at gene promoters and other selected genomic regions.

KW - BRCA1

KW - CRISPR-dCas9

KW - DNA demethylation

KW - Gene activation

KW - TET1

UR - http://www.scopus.com/inward/record.url?scp=84979911627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979911627&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10234

DO - 10.18632/oncotarget.10234

M3 - Article

C2 - 27356740

AN - SCOPUS:84979911627

VL - 7

SP - 46545

EP - 46556

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 29

ER -